Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Resolution Therapeutics Ltd.

Headquarters: Edinburgh, United Kingdom
Year Founded: 2017
Status: Private

BioCentury | Oct 4, 2024
Management Tracks

Resolution names Paul Sekhri chair

Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
BioCentury | Oct 3, 2024
Finance

Kurma investing new fund; Kailera advancing obesity assets with $400M

BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Aug 19, 2023
Management Tracks

Burrows leaving Arcutis as CFO  

Plus: Resolution names Novartis veteran Hefni as CEO and Cidara hires Davarpanah
BioCentury | May 3, 2023
Management Tracks

Filius to depart Galapagos

Plus: Modis joins Amphista as CSO and updates from ObsEva, CS Genetics, Resolution and Newron 
BioCentury | Jul 21, 2022
Management Tracks

Versanis recruits Pruzanski as CEO, adds Maraganore, Duncan to board

Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more
BioCentury | Apr 6, 2022
Product Development

April 5 Quick Takes: Short on cash, Bluebird restructures

Plus Pharma 2 B meets in Phase III and updates from Resolution, AstraZeneca and more
BioCentury | Feb 12, 2022
Emerging Company Profile

BioCentury’s 2021 class of emerging cell therapy companies

The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing 
BioCentury | Jan 26, 2021
Emerging Company Profile

Resolution: Fighting fibrosis with macrophages

Resolution is bringing macrophage cell therapies into the fibrosis arena
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

Start-up Neogene has ties to Kite veterans Belldegrun, Chang
Items per page:
1 - 9 of 9